Navigation Links
Fingerprinting prostate cancer

Two new genes which are active in prostate cancer have been identified by US researchers. At a molecular level, cancer tissue differs markedly from normal healthy tissue in its pattern of gene activity. Researchers have now developed the tools that can visualise analyse these 'molecular fingerprints' that characterise the cancerous cell. Using microarray technology, it's now possible to analyse thousands of genes in one experiments.//

Doctors at the University of Michigan have now produced the first ever molecular fingerprint of prostate cancer. They examined more than 700 prostate tissue samples from more than 50 men - covering normal tissue, tissue with benign change, and also tissues from both localised and aggressive prostate cancer. They found that more than 200 genes were expressed differently between normal and cancer tissue. Of these, some are already known to be involved in cancer, while others were completely new.

Of particular interest were two genes - hepsin and pim-1. The highest levels of hepsin were found in pre-cancerous tissue just before cancer develops, and the lowest in benign prostate tissue. Hepsin play a main role in tumour development. Pim-1, a known cancer-causing gene, was also highly expressed in prostate cancer tissue. Levels of hepsin and Pim-1 were significantly linked to prognosis, when the men's clinical histories were checked.

The researchers say that the discovery of prostate cancer's molecular fingerprint could lead to many new diagnostic tests. These could offer more to the patient than the current PSA (prostate specific antigen) test and can be used as a useful diagnostic tool.


'"/>




Page: 1

Related medicine news :

1. Better prostate cancer detection
2. Protective effects of tomatoes in prostate cancer
3. Early detection of prostate cancer
4. No link between blood groups and prostate cancer
5. Cure for osteoporosis in prostate cancer patients
6. Novel biopsy technique for prostate cancer
7. New diagnostic marker for prostate cancer
8. Inadequate proof to justify routine prostate screen
9. Combination regime may work against prostate cancer
10. Lifestyle linked to prostate cancer risk
11. Finasteride lowers risk of prostate cancer but increases risk of high-grade tumors
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ), one ... an innovative new design of the shoulder pad. The shoulder pad provides optimal ... controlling your pain while using cold therapy. By utilizing ice and water that is ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, ... post-acute health care, have expanded their existing home health joint venture through an ... has been operating a joint venture home health company with Asante, delivering clinically ...
(Date:10/12/2017)... ... October 12, 2017 , ... Dr. ... recently contributed a medical article to the newly revamped Cosmetic Town journal ... spotlights the hair transplant procedure known as Follicular Unit Extraction (FUE). ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017 AVACEN Medical , ... company with their  2017 New Product Innovation Award for ... extensive primary and secondary medical device market research by Frost ... its first-to-market OTC, drug-free pain relief product, the AVACEN 100, ... to treating fibromyalgia widespread pain. ...
(Date:10/12/2017)... EXTON, Pa. , Oct. 12, 2017 ... global leader in innovative solutions for injectable drug administration, ... results before the market opens on Thursday, October 26, ... discuss the results and business expectations at 9:00 a.m. ... 877-930-8295 (U.S.) or 253-336-8738 (International). The conference ID is ...
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
Breaking Medicine Technology: